Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Chinese Citric Acid Manufacturers Face Shakeout

This article was originally published in PharmAsia News

Executive Summary

DSM's Wuxi citric acid plant recently stopped production. Industry insiders think the shutdown has little impact on other local citric acid manufacturers and the business due to the company's small share in the China market. However, some express concern that the move indicates weaker demand for the product. Furthermore, stricter environmental standards implemented by the government, coupled with a long-term output surge and recent raw materials price hike, are putting more pressure on the highly polluting industry. Analysts observe that small, low-productivity enterprises which do not meet the environmental protection standards will inevitably be eliminated. To survive the shakeout, the industry looks set for resource consolidation to achieve significance of scale. (Click here for more - Chinese Language)

Latest Headlines
See All
UsernamePublicRestriction

Register

SC067579

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel